Pfizer Inc. / Akcea Therapeutics / Ionis Pharmaceuticals (AKCEA-ANGPTL3-LRx license)

Cardiovascular Disease / Dyslipidemia

Disease Overview

Dyslipidemia — including elevated LDL-C, non-HDL-C, and triglycerides — is the principal modifiable driver of atherosclerotic cardiovascular disease, the leading cause of death in the United States. Despite statin therapy, a substantial residual risk population exists, including patients with severe hypertriglyceridemia, familial chylomicronemia syndrome, and statin-refractory mixed dyslipidemia.

Competitive Landscape

At the time of the 2019 Pfizer-Ionis/Akcea deal, the lipid-lowering market was dominated by genericized statins (atorvastatin, rosuvastatin) supplemented by Sanofi/Regeneron's Praluent and Amgen's Repatha (PCSK9 monoclonal antibodies, ~$300-500M annual sales each at the time) and Novartis's later Leqvio (inclisiran, an siRNA targeting PCSK9, approved 2021). For severe hypertriglyceridemia and FCS, Akcea's own Waylivra (volanesorbep) and Amarin's Vascepa (icosapent ethyl) addressed niche segments. Vupanorsen (AKCEA-ANGPTL3-LRx) targeted ANGPTL3, a hepatic regulator of triglyceride and cholesterol metabolism validated by human loss-of-function genetics; the GalNAc-conjugated antisense format promised monthly subcutaneous dosing competitive with PCSK9 antibodies. Pfizer paid $250M upfront plus up to $1.3B in milestones and tiered double-digit royalties. Pfizer terminated the program in January 2022 after the TRANSLATE-TIMI 70 Phase 2b: while statistically significant non-HDL-C and TG reductions were achieved, magnitude was insufficient and a dose-dependent hepatic fat fraction increase raised safety concerns, returning rights to Ionis.